Glenmark Pharma stocks rise nearly 9% on DCGI nod for clinical trials of COVID-19 tablets

The company said it is the first firm in India to receive such an approval from the Drug Controller General of India (DCGI).

The scrip jumped 8.88 per cent to Rs 359 on the BSE.

On the NSE, it zoomed 8.88 per cent to Rs 359.

Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said in a statement.

The company is the first pharmaceutical firm in India to be given an approval by the DCGI to start the trial on COVID-19 patients, it added.

Favipiravir antiviral tablet has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections, it added.

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Free Press Journal